Tyler Jacks
Director/Board Member at THERMO FISHER SCIENTIFIC
Net worth: 9 M $ as of 2024-03-30
Profile
Tyler E.
Jacks is the founder of T2 Biosystems, Inc. (founded in 2006) and Dragonfly Therapeutics, Inc. (founded in 2016).
He currently holds positions as an Independent Director at Amgen, Inc. (since 2012), Director at Thermo Fisher Scientific, Inc. (since 2009), President & Director at Commonwealth Cancer Consortium, Inc. (since 2021), and Professor at Massachusetts Institute of Technology (since 2007).
Dr. Jacks previously served as Chairman at the National Cancer Institute and as Director at the David H.
Koch Institute for Integrative Cancer Research (from 2007 to 2021).
He received his undergraduate degree from Harvard University in 1983 and his doctorate degree from The University of California, San Francisco in 1988.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-05-23 | 8,059 ( 0.00% ) | 5 M $ | 2024-03-30 | |
AMGEN INC.
0.00% | 2023-05-18 | 14,868 ( 0.00% ) | 4 M $ | 2024-03-30 |
Tyler Jacks active positions
Companies | Position | Start |
---|---|---|
THERMO FISHER SCIENTIFIC | Director/Board Member | 2009-05-25 |
AMGEN INC. | Director/Board Member | 2011-12-31 |
Massachusetts Institute of Technology | Corporate Officer/Principal | 2006-12-31 |
Commonwealth Cancer Consortium, Inc. | President | 2021-01-31 |
Former positions of Tyler Jacks
Companies | Position | End |
---|---|---|
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Director/Board Member | 2020-12-31 |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Chairman | 2015-12-31 |
T2 BIOSYSTEMS, INC. | Founder | 2012-12-31 |
Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics, Inc. BiotechnologyHealth Technology Dragonfly Therapeutics, Inc. develops therapy to stimulate immune responses against cancer. The company was founded by Tyler Jacks, Bill Haney and David Raulet in 2015 and is headquartered in Waltham, MA. | Founder | - |
Training of Tyler Jacks
Harvard University | Undergraduate Degree |
The University of California, San Francisco | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
AMGEN INC. | Health Technology |
THERMO FISHER SCIENTIFIC | Health Technology |
T2 BIOSYSTEMS, INC. | Health Technology |
Private companies | 4 |
---|---|
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Commercial Services |
Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics, Inc. BiotechnologyHealth Technology Dragonfly Therapeutics, Inc. develops therapy to stimulate immune responses against cancer. The company was founded by Tyler Jacks, Bill Haney and David Raulet in 2015 and is headquartered in Waltham, MA. | Health Technology |
Commonwealth Cancer Consortium, Inc. |
- Stock Market
- Insiders
- Tyler Jacks